On February 25, 2020 Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, reported that Jeff Goater, chief executive officer, and Robert Ross, M.D., chief medical officer, will participate in a fireside chat at the 40th Annual Cowen Healthcare Conference, discussing Surface Oncology’s lead programs, SRF617 (targeting CD39) and SRF388 (targeting IL-27) (Press release, Surface Oncology, FEB 25, 2020, View Source [SID1234554737]). The fireside chat will take place on Tuesday, March 3, 2020 at 12 p.m. EDT at the Boston Marriott Copley Place in Boston, Mass.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live audio and subsequent archived webcasts of the Company’s presentations will be accessible from the Company’s investor relations website, investors.surfaceoncology.com.